ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ボセンタン

Bosentan

HCID 104865
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
147536-97-8
標準SMILES
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO
InChIKey
GJPICJJJRGTNOD-UHFFFAOYSA-N
分子式
C27H29N5O6S
平均分子量
551.6 g/mol
単同位体質量
551.18385484

概要

Bosentan is a primary alcohol, a sulfonamide and a member of pyrimidines. It has a role as an antihypertensive agent and an endothelin receptor antagonist.

名称と識別子

優先名称
Bosentan
IUPAC
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
現地名
ボセンタン
英語名
Bosentan
分子式
C27H29N5O6S
分子量
551.61

名称と別名

Bosentan147536-97-8Tracleerbosentan anhydrousbosentanumRo 47-0203Anhydrous bosentanRo-47-02034-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamideDTXSID7046627p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamideRo-47-0203/029
名称をさらに表示
ボセンタンボゼンタン4-tert-ブチル-N-[6-(2-ヒドロキシエトキシ)-5-(2-メトキシフェノキシ)-2,2′-ビピリミジン-4-イル]ベンゼンスルホンアミド4-tert-ブチル-N-[6-(2-ヒドロキシエトキシ)-5-(2-メトキシフェノキシ)[2,2′-ビピリミジン]-4-イル]ベンゼンスルホンアミド4-(tert-ブチル)-N-[6-(2-ヒドロキシエトキシ)-5-(2-メトキシフェノキシ)-2-(2-ピリミジニル)-4-ピリミジニル]ベンゼンスルホンアミド4-tert-ブチル-N-[6-(2-ヒドロキシエトキシ)-5-(2-メトキシフェノキシ)-[2,2'-ビピリミジン]-4-イル]ベンゼン-1-スルホンアミド4-(1,1-ジメチルエチル)-N-[6-(2-ヒドロキシエトキシ)-5-(2-メトキシフェノキシ)-2,2′-ビピリミジン-4-イル]ベンゼンスルホンアミドBosentan impurityBosentan USP/EP/BPActelionro47-0203ro47-0203/039Bosentan 13C6Bosentan - Bio-X ?bosentan , CID 104865Bosentan, 10 mM in DMSO
XUL93R30K24-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamideBenzenesulfonamide, 4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-DTXCID5026627CHEBI:514504-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamideBenzenesulfonamide, 4-(1,1-dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'-bipyrimidin)-4-yl)-Ro-470203029

物性

構造計算による物性

XLogP
3.8
極性表面積
154 Ų
水素結合供与体数
2
水素結合受容体数
11
回転可能結合数
11
重原子数
39
形式電荷
0
複雑度
839

実験および物理化学的性質

Drugs · 3 件

Pharmaceuticals

Pharmaceuticals -> Antihypertensives

Pharmaceuticals -> Listed in ZINC15

LogP · 2 件

3.7

1.99

Solubility · 2 件

Poorly soluble in water (1.0 mg/100 ml) and in aqueous solutions at low pH (0.1 mg/100 ml at pH 1.1 and 4.0; 0.2 mg/100 ml at pH 5.0). Solubility increases at higher pH values (43 mg/100 ml at pH 7.5).

9.04e-03 g/L

Human Drugs · 4 件

Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Cardiovascular Agents; Endothelin Receptor Antagonists; Vasodilator Agents

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Physical DescriptionSolid
Collision Cross Section229.9 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: APCI+; Dataset: TOXCAST; Source Identifier: DTXSID80873178]

物理化学的性質

融点
107 · 107-110°C
沸点
742.3 · 742.3±70.0 °C(Predicted)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H302 (40%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P264, P270, P273, P280, P301+P317, P318, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 5 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 4 (40%)

毒性情報

Hepatotoxicity · 1 件

Bosentan is associated with elevations in serum aminotransferase levels above three times the upper limit of the normal range (ULN) in 3% to 18% of patients, averaging 7.6% using currently recommended doses. The enzyme elevations are usually self-limited and are rarely accompanied by symptoms, but can be more marked and persist and require dose reduction or discontinuation (in 3% to 4% of patients). Monthly monitoring of serum aminotransferase levels is recommended, with discontinuation for levels above 8 times the ULN or for values above 5 times the ULN that persist. There have also been rare reports of clinically apparent liver injury with jaundice associated with bosentan use. The onset of illness was usually within 1 to 6 months of starting bosentan, but cases arising during chronic therapy have also been described (Case 1). The enzyme pattern has typically been hepatocellular or mixed. Immunoallergic features are usually not present and autoantibodies are usually absent or present in low titer. Some cases have been severe and fatalities have been reported, but there have been no published reports of chronic hepatitis or vanishing bile duct syndrome attributed to bosentan. Autoimmune and immunoallergic features are usually not present.

Adverse EffectsSafety Profile

化学と産業

薬理情報

ATC Code · 3 件

C02KX01

C - Cardiovascular system

QC - Cardiovascular system

Protein BindingGreater than 98% to plasma proteins, mainly albumin.
Pharmacodynamics · 1 件

Bosentan belongs to a class of drugs known as endothelin receptor antagonists (ERAs). Patients with PAH have elevated levels of endothelin, a potent blood vessel constrictor, in their plasma and lung tissue. Bosentan blocks the binding of endothelin to its receptors, thereby negating endothelin's deleterious effects.

Mechanism of Action · 1 件

Endothelin-1 (ET-1) is a neurohormone, the effects of which are mediated by binding to ET<sub>A</sub> and ET<sub>B</sub> receptors in the endothelium and vascular smooth muscle. It displays a slightly higher affinity towards ET<sub>A</sub> receptors than ET<sub>B</sub> receptors. ET-1 concentrations are elevated in plasma and lung tissue of patients with pulmonary arterial hypertension, suggesting a pathogenic role for ET-1 in this disease. Bosentan is a specific and competitive antagonist at endothelin receptor types ET<sub>A</sub> and ET<sub>B</sub>.

Biological Half-LifeTerminal elimination half-life is about 5 hours in healthy adult subjects.
Metabolism/Metabolites · 2 件

Bosentan is metabolized in the liver by the cytochrome P450 enzymes CYP2C9 and CYP3A4 (and possibly CYP2C19), producing three metabolites, one of which, Ro 48-5033, is pharmacologically active and may contribute 10 to 20% to the total activity of the parent compound.

Bosentan has known human metabolites that include 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)-[2,2-]bipyrimidinyl-4-yl]-benzenesulfonamide and Hydroxy Bosentan.

FDA Pharmacological Classification · 6 件

XUL93R30K2

BOSENTAN ANHYDROUS

Established Pharmacologic Class [EPC] - Endothelin Receptor Antagonist

関連反応

16 件
反応記録を作成
HRID 97752 の反応式
HRID 97752生成物として
HRID 397262 の反応式
HRID 397262反応物として
HRID 448549 の反応式
HRID 448549生成物として
HRID 448550 の反応式
HRID 448550生成物として
HRID 448551 の反応式
HRID 448551生成物として
HRID 954007 の反応式
HRID 954007生成物として
HRID 1020775 の反応式
HRID 1020775生成物として
HRID 1020776 の反応式
HRID 1020776生成物として
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
147536-97-8
PubChem CID
104865
DTXSID
DTXSID7046627
ChEMBL
CHEMBL957
ChEBI
CHEBI:51450
UNII
XUL93R30K2
EC Number
643-099-1
Nikkaji
J594.472D
比重(密度)
1.325 · 1.325±0.06 g/cm3(Predicted)
貯蔵温度
-20 °C · -20°C Freezer
溶解性
DMSO(微量)、メタノール(微量)
外見
個体
酸解離定数(Pka)
4.01 · 4.01±0.10(Predicted)
色
ホワイトからペールイエロー
CAS データベース
147536 · 147536-97-8(CAS DataBase Reference)

化学的性質

化学的特性Pale Yellow to Off-White Solid

Toxicity Summary · 1 件

The most frequently observed adverse effect of bosentan overdose is headache. In a cyclosporine A interaction study, administration of 500 mg and 1,000 mg of bosentan twice daily in combination with cyclosporine A resulted in a 30-fold increase in trough plasma concentrations, leading to severe headache, nausea, and vomiting. No serious adverse events were reported. Additional findings included hypotension and tachycardia.

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Bosentan

vMost-DILI-concern

7

Box warning

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

hs_code
29350090

Mechanisms of Action [MoA] - Endothelin Receptor Antagonists

Mechanisms of Action [MoA] - Cytochrome P450 3A Inducers

Mechanisms of Action [MoA] - Cytochrome P450 2C9 Inducers

MeSH Pharmacological Classification · 2 件

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN RECECPTORS.

Absorption, Distribution and Excretion · 4 件

Absolute bioavailability is approximately 50% and food does not affect absorption.

Bosentan is eliminated by biliary excretion following metabolism in the liver.

18 L

4 L/h [patients with pulmonary arterial hypertension]

Cellular LocationsMembrane

用途と製造

UsesUse (kg; approx.) in Germany (2009): >100
応用分野 · 2 件

使用A mixed endothelin receptor antagonist. Used as a vasodilator. Antihypertensive.

一般的な説明Bosentan, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]-4-tertbutyl-benzenesulfonamide (Tracleer, Bozentan), was thefirst endothelin receptor antagonist marketed in the UnitedStates. Bosentan works by competitively blocking the endothelinreceptor subtypes ETA and ETB. In binding to thereceptors, it blocks the effects of endothelin, which includeconstriction of the vascular smooth muscle, which leads tonarrowing of the blood vessels and hypertension. Althoughit is not selective for the ETA receptors, it does have a higheraffinity for that subtype over ETB. However, the clinical significanceof selectivity over preferential receptor bindinghas not been demonstrated. Bosentan is an inducer ofCYP2C9 and CYP3A4, and patients using bosentan must bemonitored for liver toxicity.

上流・下流製品情報

上流原料

L-(+)-酒石酸エチレングリコールbeta-(4-Chlorophenyl)glutaric anhydrideナトリウム2-ピリミジンカルボキシイミドアミド塩酸塩4,6-ジクロロ-5-(2-メトキシフェノキシ)-2,2’-ビピリミジンD-(-)-酒石酸2-(2-メトキシフェノキシ)マロン酸ジエチル